While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized … Continue reading “NetworkNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product”
The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of … Continue reading “Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia”
Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026 19 patent applications filed and pending in more than 40 countries Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues Showcasing Proprietary Research at Cannabis Investment Conferences”
Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships LXRP names Allan Spissinger acting chief financial officer Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council (“NRC”) … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Begins Laboratory Venture with National Research Council”
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced the world’s first clinical study on human volunteers of cannabidiol (CBD) within Lexaria’s TurboCBD™ product. The study, which aims to evaluate the effects of TurboCBD™ on both cardiovascular health and cognitive function, … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Announces Clinical Study of High Absorption TurboCBD™ Product”
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a company engaged in licensing proprietary technology for the delivery of bioactive compounds, this morning announced its plans to attend two cannabis investment conferences in September. The first, the Investorshub International Cannabis Conference, will be held at the JW Marriott in downtown Los Angeles on September 1-2. The … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Scheduled to Attend Two Cannabis Conferences in September”
Common complaints among consumers of cannabis edibles include the presence an unpleasant taste, but this and other inadequacies are being overcome through the innovations of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria’s disruptive process masks the unpleasant taste of cannabis, and the company’s lipophilic enhancement technology also changes the way cannabinoids enter the body … Continue reading “NetworkNewsBreaks – Disruptive Process Pioneered by Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Creates Superior Cannabis Edibles”
19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues to Deliver Results with its Patented Technology”
Disruptive, patented technology is set to revolutionize the edible cannabis market Company has patent applications in 45 countries, including 18 applications in the U.S. Technology is patent-protected for CBD and all other non-psychoactive cannabinoids, with patents pending for THC, other psychoactive cannabinoids, NSAIDs, nicotine and other molecules A common complaint among the consumers of cannabis … Continue reading “Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Revolutionary Process Creates Superior Cannabinoid Edibles”
In an interview with Stock Day, CEO Chris Bunka of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) discussed the company’s recent achievements and its plans for the near future. Revenues are climbing, exceeding, so far in 2017, the total for all of 2016, and the potential for further increases is imminent. The company is in … Continue reading “Regulation Forcing Drug and Cigarette Companies to Be More Responsible is Great News for Lexaria (LXRP), says CEO”
